Trial Profile
Prospective Phase II Study of Gemcitabine Plus Platinium Salt in Combination With Bevacizumab (Avastin®) for Metastatic Collecting Duct Carcinoma
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Bevacizumab (Primary) ; Gemcitabine (Primary) ; Carboplatin; Cisplatin
- Indications Renal cell carcinoma
- Focus Therapeutic Use
- Acronyms BEVABEL
- 04 Mar 2021 Status changed from recruiting to completed.
- 21 Sep 2020 Primary endpoint (Composite endpoint : Objective response rate / Progression-free survival) has not been met.
- 21 Sep 2020 Results presented at the 45th European Society for Medical Oncology Congress